|
UBE2D4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.19850051894366E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.50440026891863E-10 |
| Normal-vs-Stage2 |
8.626500E-02 |
| Normal-vs-Stage3 |
8.6007000410504E-09 |
| Normal-vs-Stage4 |
4.03399535997551E-12 |
| Stage1-vs-Stage2 |
8.499800E-03 |
| Stage1-vs-Stage3 |
2.316200E-01 |
| Stage1-vs-Stage4 |
4.115500E-03 |
| Stage2-vs-Stage3 |
1.337530E-03 |
| Stage2-vs-Stage4 |
7.90430000000564E-05 |
| Stage3-vs-Stage4 |
1.667980E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.5807801996034E-12 |
| Normal-vs-AfricanAmerican |
4.26630000005535E-06 |
| Normal-vs-Asian |
2.42990000343113E-08 |
| Caucasian-vs-AfricanAmerican |
9.557200E-01 |
| Caucasian-vs-Asian |
9.501400E-01 |
| AfricanAmerican-vs-Asian |
9.925200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.38560290913392E-11 |
| Normal-vs-Female |
1.497599999567E-08 |
| Male-vs-Female |
1.209370E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.49790180259401E-11 |
| Normal-vs-Age(41-60Yrs) |
3.64060004365285E-10 |
| Normal-vs-Age(61-80Yrs) |
2.000700E-04 |
| Normal-vs-Age(81-100Yrs) |
2.563000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.667600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.153700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.145000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.923700E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.321200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.178600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.686960E-01 |
| Classical-VS-Follicular |
1.11688436277291E-12 |
| Classical-VS-Other |
5.050600E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
1.15170095682515E-11 |
| Tall-VS-Other |
1.407780E-01 |
| Tall-VS-Normal |
4.2579273440424E-12 |
| Follicular-VS-Other |
5.142100E-02 |
| Follicular-VS-Normal |
8.346600E-01 |
| Other-VS-Normal |
6.063800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.83593999999454E-05 |
| Normal-vs-N1 |
2.8110846983509E-13 |
| N0-vs-N1 |
1.11369999999944E-06 |
|
|
